Short answer
Candel Therapeutics, Inc. (CADL) filed an 8-K current report with the SEC on November 12, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q3 2026 financial results announced for quarter ended September 30, 2026.
Candel Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q3 2026 financial results announced for quarter ended September 30, 2026
- Full results and management commentary available in Exhibit 99.1
- Investor focus: clinical-development spending, cash runway and pipeline progress in the accompanying release
Item EX-99.1 · Exhibit EX-99.1
- Q3 revenue-free biotech reported net loss $21.9M, versus $11.3M, with R&D spending rising to $15.6M to advance aglatimagene programs
- Cash $203.1M, up from $119.7M at year-end, supports operations into Q2 2028 under current plans, reducing near-term financing pressure
- Prostate cancer BLA submission now targeted for mid-2027, pending FDA dialogue and assay refinement, delaying a key regulatory catalyst
- Phase 3 data showed 41% lower recurrence or prostate cancer-specific death risk, while 80% of evaluable patients had negative biopsies versus 63% for control
- NSCLC pivotal AURORA trial initiated across approximately 150 planned sites, while linoserpaturev showed 12.0-month median survival in 50 recurrent glioma patients
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Candel Therapeutics, Inc. 8-K filings
Get the next CADL 8-K as it lands
Follow CADL for push alerts, or ask the research agent what this filing means.